Everand Logo

Welcome to Everand!

  • STAT

    After forced sale, PatientsLikeMe founder frets that U.S. policy could chill collaboration in biotech

    PatientsLikeMe founder speaks publicly for the first time about the U.S. order that the company must find a new buyer.
    by Matthew Herper May 20, 2019 4 minutes
    Source: DANIEL LEAL-OLIVAS/AFP/Getty Images

    Jamie Heywood is a live wire of a man, a thin, energetic mechanical engineer who entered the biotech world after his brother was diagnosed with amyotrophic lateral sclerosis in 1998. Seeing the state of basic science around the disease, he started the world’s first nonprofit biotechnology company, ALS TDI, with his family. From that moment, he was never one to mince words.

    So he made his frustration clear when he spoke for the first time publicly about what has been happening to his second company, PatientsLikeMe, which is being an investment by China-based iCarbonX. At the conference where Heywood appeared recently, the Convergence Forum on Cape Cod, the room took on the tenor of a wake as he spoke about the

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
    Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
    Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

    Related Books & Audiobooks